Safety of L1-79 in Adolescent and Adult Males With Autism

Completed · Phase 2 · Has a placebo group

Conditions studied: Autism

In brief

This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days. The open label patients will be assessed for the purpose of understanding PK/PD and to determine if there are any EKG changes associated with the administration of L1-79. Additional safety information will be provided by the 30 patients randomized 2:1 active:placebo.

Key facts

Study ID
NCT02947048
Run by
Yamo Pharmaceuticals LLC
People needed
42
Starts
2016-10-01
Expected to finish
2018-02-01
Last updated by the study team
2024-08-21

Who can join

Age: 12 and older, up to 21. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.